$GWPH Jumps: Stock Rises 13.1% – Tale of the Tape

GW Pharmaceuticals plc (GWPH) was a big mover last session with its shares rising just over 13% on the day. The upside was owing to the company’s announcement that the American Academy of Neurology (AAN) has released data from physician-led FDA authorized Epidiolex “expanded access” programs for children and young adults with treatment-resistant epilepsy who have exhausted available treatment options. This development led to far more shares changing hands yesterday than in a normal session. This breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $86.46 to $100.48.

This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

GW Pharmaceuticals currently holds a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.